Healthy Masters

SPEAKER

LIZ PARRISH

LIZ PARRISH

Founder and CEO of BIOVIVA SCIENCES USA Inc.

LIZ PARRISH

Elizabeth Parrish is the Founder and CEO of BioViva, a company committed to extending healthy lifespans using cell technologies. Liz is a humanitarian, entrepreneur, innovator, and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of regenerative medicine modalities, she serves as a motivational speaker to the public at large for the life sciences. She is actively involved in international educational media outreach and is a founding member of the International Longevity Alliance (ILA). She is an affiliated member of the Complex Biological Systems Alliance (CBSA), which is a unique platform for Mensa based, highly gifted persons who advance scientific discourse and discovery. The mission of the CBSA is to further scientific understanding of biological complexity and the nature and origins of human disease. She is the founder of BioTrove Investments LLC and the BioTrove Podcasts which is committed to offering a meaningful way for people to learn about and fund research in regenerative medicine.

watch video

Liz Parrish’s main goal is to live forever or at least to extend human life indeterminately. That’s why she created BioViva.
Liz, willing to find the answer to her goal, made a treatment. Until then, this treatment had only been tested on rats. But Liz took a chance and although she
didn’t notice any sudden effect, she didn’t regret it.
A few years earlier, Liz had discovered that her son had type 1 diabetes. Faced with the reality of that disease and the lack of a cure, Liz went looking for answers.
At one event she met Dr. Aubrey De Grey, one of our speakers, the result of a conversation was a partnership between Parrish and Dr. Andrews, who began working
on a genetic treatment for Parrish’s company, BioViva.
In addition, BioViva is following a new path to bioinformatics. The idea is to start using artificial intelligence and machine learning to develop new gene therapies.